Not Yet Recruiting PHASE1 INTERVENTIONAL 4-arm
NCT07390539
B7-H3.CD28Z.CART in CNS Neoplasms
A Phase 1/1b Study of Autologous b7-h3 Chimeric Antigen Receptor t Cells (b7-h3.cd28z.Cart) in Children and Young Adults With Recurrent or Progressive Cns Neoplasms Expressing b7-h3 Target
Sponsor: National Institutes of Health (NIH)
Conditions
Atypical Teratoid/Rhabdoid Tumor Brain Tumor Brain Tumor Adult Brain Tumor, Pediatric Brain Tumor, Recurrent Central Nervous System Neoplasms Embryonal Tumor With Multilayered Rosettes Ependymoma Leptomeningeal Disease Medulloblastoma Medulloblastoma Recurrent Medulloblastoma, Adult Medulloblastoma, Childhood Pineoblastoma
Interventions
B7-H3.CD28Z.CART Cyclophosphamide Fludarabine
Updated 1 time since 2026 Last updated: Jan 28, 2026 Started: Jul 31, 2026 Primary completion: Aug 31, 2030 Completion: Aug 31, 2032
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Atypical Teratoid/Rhabdoid Tumor and Brain Tumor and is currently actively recruiting participants. National Institutes of Health (NIH) leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- National Institutes of Health (NIH)
- Robbie Majzner
Data source: Dana-Farber Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .